9/29/ Disclosure. Learning Objectives. Diabetes Update: Guidelines, Treatment Options & Trends

Size: px
Start display at page:

Download "9/29/ Disclosure. Learning Objectives. Diabetes Update: Guidelines, Treatment Options & Trends"

Transcription

1 + Diabetes Update: Guidelines, Treatment Options & Trends Melissa Max, PharmD, BC-ADM, CDE Assistant Professor of Pharmacy Practice Harding University College of Pharmacy + Disclosure Conflicts Of Interest and Financial Relationships Disclosures: Melissa Max, PharmD, BC-ADM, CDE No COI/Financial Relationships to Disclose. Learning Objectives Analyze differences between the recommendations of the ADA/EASD and the AACE regarding the treatment of diabetes. Interpret recent recommendations regarding interventions for patients with prediabetes/at increased risk for developing diabetes. Describe the place in therapy for newer pharmacotherapeutic agents. Apply knowledge of evidence-based recommendations to specific patient cases. Identify trends in pharmacotherapeutic management of diabetes. 1

2 + Type 2 Diabetes (T2D) Overview Hallmarks of T2D Decreased insulin sensitivity Progressive loss of β cell function Therapeutic goals are not exclusively glucocentric Optimizing physical activity, weight loss and healthy eating are key Progressive disease Monotherapy failure Next steps? + Inpatient Use Insulin remains gold standard Significant concerns regarding the use of metformin, secretagogues and GLP1 RAs in inpatient setting Imperative that pharmacists be familiar with various diabetes pharmacotherapeutic agents as patients will be admitted and discharged on these therapies + Current Guidelines American Diabetes Association annual clinical practice recommendations, released each January American Diabetes Association and European Association for the Study of Diabetes 2012 Position Statement for T2D American Association of Clinical Endocrinologists Comprehensive Diabetes Management Algorithm

3 9/29/2014 Diabetes Care 2012;35: Diabetologia 2012;55: ADA/EASD Summary Metformin first line Consider insulin as initial therapy if significant hyperglycemia or high A1C If noninsulin monotherapy not effective over 3 months, add a second oral agent, GLP-1 agent, or insulin Each new class of agent added lowers A1C ~1% 3

4 + AACE & ADA/EASD Comparison AACE A1C target <6.5% Monotherapy if A1C < 7.5% Dual therapy for A1C 7.6-9% Consider use of insulin as initial therapy A1C > 9% Focus on total cost of therapy ADA/EASD A1C target < 7%* May consider lifestyle alone for 3 months if A1C < 7.5% Dual therapy if A1C 9% Consider use of insulin as initial therapy A1C 10% 4

5 + Multifactorial Interventions Glucose lowering Lipid modification Optimal CV risk reduction Lifestyle modification & tobacco cessation BP lowering Goals for Glycemic Control ADA 1 AACE 2 A1C (%) <7 a 6.5 Fasting/preprandial glucose Peak postprandial glucose mg/dl <110 mg/dl <180 mg/dl <140 mg/dl b a Goal for most adult patients. Goal for individual patients is A1C as close to normal (<6%) as possible without significant hypoglycemia. b 2-hour postprandial. 1. ADA Position Statement Available at: 2. AACE Guidelines Available at: + Individualization of A1C Goal Tighter targets ( %) younger, healthier Looser targets ( % or more) older, comorbidities, risk of hypoglycemia Avoidance of hypoglycemia 5

6 + Diabetes Care 2012;35: Diabetologia 2012;55: (Adapted with permission from: Ismail-Beigi et al. Ann Intern Med 2011;154:554) + Antihyperglycemic Therapy Nonpharmacologic Weight optimization Healthy diet Increased physical activity Pharmacotherapeutic options Oral agents Parenterals Non-insulin GLP-1 RA Amylin mimetic Insulin + 12 Drug Classes Biguanides Sulfonylureas Meglitinides Thiazolidinediones Alpha Glucosidase Inhibitors Dopamine-2 Agonists Bile Acid Sequestrants DPP-4 Inhibitors GLP-1 Receptor Agonists* Amylin Mimetic* Insulin* Sodium Glucose Co- Transporter-2 (SGLT2) Inhibitors 6

7 + Drug Selection Considerations Duration of disease Which blood glucose level is not at target Patient preference for route of administration The degree of A1C-lowering effect required to achieve goal Adverse effect profile and the patient s tolerability Comorbidities + Primary Glucose Lowering Effect Fasting Metformin TZD SU Long-acting insulin Post-prandial GLP-1 Agonists* DPP-4 Inhibitors SU Rapid-acting insulin Alpha-glucosidase inhibitors Meglitinides Pramlintide + Weight Weight Loss/Neutral GLP-1 Agonists* DPP4 Inhibitors (neutral) SGLT2 Inhibitors Weight Gain Insulin SU TZD Metformin (neutral) Pramlintide 7

8 + Pharmacotherapy Pearls + SU Cautions Risk of hypoglycemia is substantially increased in the elderly Even a mild episode of hypoglycemia may lead to adverse outcomes in frail elderly patients. Avoidance of hypoglycemia is an important consideration in choosing therapeutic agents and establishing glycemic goals in elderly adults. Effective dose generally about ½ maximum dose + Sulfonylureas (SU) Avoid glyburide in older adults Assess patients for hypoglycemia regularly More likely to occur: After exercise/missed meals Eat poorly or abuse alcohol Impaired renal or cardiac function Following hospitalization In patients with T2D, hypoglycemia risk is linked more to treatment strategies than A1C If recurrent/severe hypoglycemia occurs, strongly consider changing therapy and/or targets 8

9 + Metformin Cautions Use in renal dysfunction CI: Scr> 1.5 mg/dl male, > 1.4 mg/dl female Decrease dose if GFR < 45, d/c if < 30 Other cautions Heart failure History of alcoholism/binge drinking Age > 80 years Active liver disease GI intolerance & weight loss Hypoxic conditions lactic acidosis Iodinated contrast material + Metformin Pearls Effective treatment dose generally mg daily Patient counseling GI distress in ~30%, transient Administer with meals, consider XR formulation B12 + TZD Pearls May be used in renal impairment Do not cause hypoglycemia Should not be used in patients with class III or IV HF AE: edema, fractures, bladder CA 9

10 + Recent Approvals SGLT2 Inhibitors Canagliflozin Dapagliflozin Empagliflozin DPP4 Inhibitor/Combo Alogliptin Alogliptin + metformin Alogliptin + pioglitazone + Recent Approvals GLP1 Agonist Albiglutide Once weekly; SQ 30 mg once weekly; may increase to 50 mg once weekly if inadequate glycemic response New Indication Liraglutide 3 mg daily FDA committee recommendation 9/12/14 + SGLT2 Inhibitors Sodium-glucose co-transporter type 2 (SGLT2) Inhibitors MOA: inhibition of SGLT2 receptors in kidney responsible for glucose reabsorption in proximal tubule Action reduce reabsorption of filtered glucose, lower the renal threshold for glucose, and increase urinary glucose excretion Insulin independent MOA; decreases fasting and post-prandial glucose concentrations 10

11 + SGLT2 Pearls Benefit Weight loss Blood pressure Low incidence of hypoglycemia Pleiotropic benefit Similar to DPP4 inhibitors in A1C lowering efficacy AE/Risk Genital mycotic infections UTI Hypotension Lipid effects Renal effects Bladder cancer + SGLT2 Dosing & Administration Canagliflozin mg daily dose; before the first meal of the day Moderate renal impairment [egfr] 45 to 59 ml/min max dose 100 mg daily Not indicated in patients with GFR <45 ml/min or in patients with severe hepatic impairment Dapagliflozin 10 mg once daily, with or without food Not recommended for use in patients with egfr < 60 ml/min or in patients with active bladder cancer For patients with severely reduced liver function, starting dose of 5 mg is recommended + SGLT2 Dosing & Administration Empagliflozin 10 mg and 25 mg tablet CI Severe renal impairment (egfr <30 ml/minute/1.73 m2) ESRD or dialysis Anticipated availability currently undetermined 11

12 + SGLT2 Place in Therapy Add-on to metformin, after trying usual second-line therapies Not mentioned in the ADA guidelines, as these guidelines were published before the approval of SGLT2 inhibitors The AACE consider these agents to use with caution: as monotherapy in patients with an A1C less than 7.5%; as part of a dual or triple regimen in those with an A1C of 7.5% to 9.0%. Incretin Hormones + DPP- 4 Inhibitors MOA: prolong the t½ of GLP-1 and stimulate glucosedependent insulin secretion, reducing postprandial glucose elevations Efficacy: decrease A1C 0.7-1% Adverse effects: Upper respiratory infections, UTI, HA Pancreatitis Low incidence of hypoglycemia Weight neutral 12

13 + DPP-4 Inhibitors Sitagliptin Dose: mg daily CrCl 50 ml/min, dose is 100 mg daily CrCl <50 but 30 ml/min, dose is 50 mg daily CrCl <30 ml/min, dose is 25 mg daily Linagliptin Dose: 5 mg daily + DPP-4 Inhibitors Saxagliptin Dose: mg daily 2.5 mg dose for patients with CrCl 50 ml/min Alogliptin Dose mg daily Reduce by half for patients with CrCl ml/min + DPP- 4 Inhibitors: Place in Therapy ADA considers these as second-line therapies to be added on to metformin. AACE recommends these as one of several preferred agents, after metformin, as monotherapy. They can be used as part of a dual therapy regimen. They can be considered as part of a multi-drug regimen with metformin, in drug-naïve, asymptomatic patients with A1C > 9%. 13

14 + GLP-1 Receptor Agonists MOA: similar to human GLP-1 Enhance insulin secretion Suppress postprandial glucagon when blood glucose elevated; reduce hepatic glucose production Exenatide, exenatide extended-release Liraglutide Albiglutide + GLP-1 Agonists Benefit Weight loss Low risk of hypoglycemia Efficacy Blood pressure/lipid improvement β-cell preservation Risk/Disadvantage Expensive Injectable dosage form Pancreatitis Renal insufficiency Thyroid cell cancer in rodents long-acting formulations N&V Gastroparesis + GLP-1 Agonists: Place in Therapy ADA considers these as second-line therapies to be added on to metformin, if target A1C not met. AACE recommend these as the preferred agent, after metformin, as monotherapy or as first choice of agents for add-on therapy to metformin in patients with A1C values 6.5% to 7.5%, or as metformin addon therapy for A1C of 7.6% to 9%. Additionally, these agents can be considered as part of a multi-drug regimen with metformin, in drugnaïve, asymptomatic patients with A1C > 9%. 14

15 + New GLP-1 RA formulation FDA has approved extended-release exenatide in a pen form. Indication adjunctive therapy, T2D Dose 2 mg SQ once weekly Advantage Ease the self-injection process by eliminating the need for the patient to transfer the medication between vial and syringe. Efficacy Up to 1.6% reduction in A1C + Emerging therapies + Insulins Ultra rapid-acting Afrezza Insulin human (rdna origin); ultra rapid-acting mealtime inhalable powder Approved July 2014 Lung function testing Less hypoglycemia 15

16 + Ultra rapid-acting Conversion + Ultra Long-Acting Insulins Insulin degludec Approved EU; FDA rejected Feb 2013; requested additional safety data Consistency, efficacy, safety, flexibility Peg-lispro Phase III trials complete; NDA expected first quarter 2015 Improved glycemic control; IMAGINE-1 & IMAGINE-3 U300 EDITION II less nocturnal hypoglycemia compared to glargine Flatter and longer PK/PD profile; DOA 40 hours + Insulin Combination Insulin degludec + insulin aspart Fixed combination basal with bolus Once-daily for T1 and T2 (remaining meals with aspart) Rejected Feb 2013 by FDA; requested additional CV data 16

17 + Trends Increasing use of basal insulin and GLP1 RA More effective at lowering A1C Not associated with increased hypoglycemia Weight loss Insulin and SGLT2 inhibition Prevention of disease progression in patients at increased risk for developing diabetes + GLP1/Insulin Combinations Insulin degludec and liraglutide Once-daily basal insulin and once-daily GLP-1 analogue T2DM Lixisenatide and insulin glargine GLP-1 agonist and basal insulin analog T2DM + Pipeline Incretins GLP-1 RA Lixisenatide Once daily for T2D NDA expected 2015 Dulaglutide Once weekly T2D AWARD; REWIND Semaglutide Once-weekly T2D SUSTAIN DPP4 inhibitor Omarigliptin Once-weekly, adults, T2 Phase III trials Trelagliptin succinate Once-weekly for T2D Phase III trials 17

18 + Case 1 A 47-year-old woman, newly diagnosed with T2D, presents with an A1C of 11.6% and a fasting glucose concentration of 350 mg/dl. In addition to improvements in physical activity and food choices, which one of the following is the best initial treatment option for this patient? A. Metformin B. Extended release exenatide C. Insulin glargine and insulin aspart D. Canagliflozin + Case 2 Which one of the following drugs, if coadministered with exenatide, would be most likely to increase hypoglycemia risk? A. Metformin B. Glyburide C. Saxagliptin D. Pioglitazone + Case 3 A 52-year-old woman with a 10-year history of T2D has an A1C of 7.6%. She has a history of metformin intolerance. Current antihyperglycemic therapy is pioglitazone 45 mg/day. Her SCr is 2.1 mg/dl, and her estimated CrCl is 26 ml/minute. Which one of the following would be most appropriate to add to this patient s drug regimen? A. Sitagliptin 100 mg/day B. Liraglutide 0.6 mg/day C. Extended-release exenatide 2 mg/week D. Linagliptin 5 mg/day 18

19 + Case 4 HW is a 45-year-old obese white male with T2D, currently receiving metformin 1 g twice daily, whose postprandial BG is higher than desired. His most recent A1C is 7.5%. Which of the following is the best option for HW? A. increase metformin to 850 mg three times daily B. substitute metformin with a SU C. add a bedtime dose of insulin detemir D. add sitagliptin 100 mg daily + Questions? + References American Diabetes Association American Association of Clinical Endocrinologists Standards of Medical Care in Diabetes Diabetes Care. January 2014; 35: S11-S63 Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European ssociation for the Study of Diabetes (EASD); Diabets Care June : DeFranzo, R.A., Davidson, J.A., & del Prato, S. (2012). The role of the kidneys in glucose homeostasis: A new path towards normalizing glycaemia. Diabetes, Obesity & Metabolism, 14 (1), Inzucchi, S. Oral Antihyperglycemic Therapy for Type 2 Diabetes: Scientific Review. JAMA. 2002; 287: DeWitt, D. Outpatient Insulin Therapy in Type 1 and Type 2 Diabetes Mellitus: Scientific Review. JAMA. 2003;289:

Joshua Settle, PharmD Clinical Pharmacist Baptist Medical Center South ALSHP Fall Meeting September 30, 2016

Joshua Settle, PharmD Clinical Pharmacist Baptist Medical Center South ALSHP Fall Meeting September 30, 2016 Joshua Settle, PharmD Clinical Pharmacist Baptist Medical Center South jjsettle@baptistfirst.org ALSHP Fall Meeting September 30, 2016 Objectives Describe the current information concerning newly approved

More information

Antihyperglycemic Agents in Diabetes. Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014

Antihyperglycemic Agents in Diabetes. Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014 Antihyperglycemic Agents in Diabetes Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014 Objectives Review 2014 ADA Standards of Medical Care in DM as they

More information

Update on Therapies for Type 2 Diabetes: Angela D. Mazza, DO July 31, 2015

Update on Therapies for Type 2 Diabetes: Angela D. Mazza, DO July 31, 2015 Update on Therapies for Type 2 Diabetes: 2015 Angela D. Mazza, DO July 31, 2015 Objectives To present the newer available therapies for the management of T2D To discuss the advantages and disadvantages

More information

What s New in Diabetes Medications. Jena Torpin, PharmD

What s New in Diabetes Medications. Jena Torpin, PharmD What s New in Diabetes Medications Jena Torpin, PharmD 1 Objectives Discuss new medications in the management of diabetes Understand the mechanism of the medications discussed Understand the side effects

More information

Oral and Injectable Non-insulin Antihyperglycemic Agents

Oral and Injectable Non-insulin Antihyperglycemic Agents Appendix 5: Diabetes Education and Medical Management in Adults with Diabetes Oral and Injectable Non-insulin s This directive will be implemented by RPhs, RNs or RDs who have been deemed authorized implementers.

More information

Type 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions

Type 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions Diabetes Mellitus: Complications and Co-Morbid Conditions ADA Guidelines for Glycemic Control: 2016 Retinopathy Between 2005-2008, 28.5% of patients with diabetes 40 years and older diagnosed with diabetic

More information

What s New in Type 2 Diabetes? 2018 Diabetes Updates

What s New in Type 2 Diabetes? 2018 Diabetes Updates What s New in Type 2 Diabetes? 2018 Diabetes Updates Gretchen Ray, PharmD, PhC, BCACP, CDE Associate Professor, UNM College of Pharmacy January 28, 2018 gray@salud.unm.edu OBJECTIVES Describe the most

More information

What s New on the Horizon: Diabetes Medication Update

What s New on the Horizon: Diabetes Medication Update What s New on the Horizon: Diabetes Medication Update Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors, and what s coming Revised ADA/EASD and AACE guidelines:

More information

What s New in Diabetes Treatment. Disclosures

What s New in Diabetes Treatment. Disclosures What s New in Diabetes Treatment Shiri Levy M.D. Henry Ford Hospital Senior Staff Physician Service Chief, West Bloomfield Hospital Endocrinology, Metabolism, Bone and Mineral Disorders Disclosures None

More information

Pharmacology Update for the Adult Patient - Newer Oral Medications for Diabetes

Pharmacology Update for the Adult Patient - Newer Oral Medications for Diabetes Pharmacology Update for the Adult Patient - Newer Oral Medications for Diabetes Brooke Hudspeth, PharmD, CDE, MLDE Director of Diabetes Prevention, Kroger Pharmacy Adjunct Assistant Professor, University

More information

What s New on the Horizon: Diabetes Medication Update. Michael Shannon, MD Providence Endocrinology, Olympia WA

What s New on the Horizon: Diabetes Medication Update. Michael Shannon, MD Providence Endocrinology, Olympia WA What s New on the Horizon: Diabetes Medication Update Michael Shannon, MD Providence Endocrinology, Olympia WA 1 Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors,

More information

GLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary

GLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) s (Byetta/exenatide, Bydureon/ exenatide extended-release, Tanzeum/albiglutide, Trulicity/dulaglutide, and Victoza/liraglutide) Step Therapy

More information

Peter Stein, MD Janssen Research and Development

Peter Stein, MD Janssen Research and Development New Agents and Technologies in the Pipeline for the Treatment of Patients with Diabetes Peter Stein, MD Janssen Research and Development Agents in Phase 3 Development for T2DM Long-acting GLP-1 analogues

More information

Newer Drugs in the Management of Type 2 Diabetes Mellitus

Newer Drugs in the Management of Type 2 Diabetes Mellitus Newer Drugs in the Management of Type 2 Diabetes Mellitus Dr. C. Dinesh M. Naidu Professor of Pharmacology, Kamineni Institute of Medical Sciences, Narketpally. 1 Presentation Outline Introduction Pathogenesis

More information

Table 1. Antihyperglycemic agents for use in type 2 diabetes

Table 1. Antihyperglycemic agents for use in type 2 diabetes Table 1. Antihyperglycemic agents for use in type 2 diabetes DRUG IN ALPHA-GLUCOSIDASE INHIBITOR: inhibits pancreatic alpha-amyle and intestinal alpha-glucoside Acarbose (Glucobay) 0.6% Negligible Not

More information

NEW DIABETES CARE MEDICATIONS

NEW DIABETES CARE MEDICATIONS NEW DIABETES CARE MEDICATIONS James Bonucchi DO, ECNU, FACE Adult Medicine and Endocrinology Specialists Disclosures Speakers bureau Sanofi AZ BI Diabetes Diabetes cost ADA 2017 data Ever increasing disorder.

More information

Updates in Diabetes Care

Updates in Diabetes Care Updates in Diabetes Care Disclosures Nothing to disclose Pharmacist Objectives 1. List strategies for improving diabetes care 2. Understand benefits and risks associated with newer pharmacotherapeutic

More information

DIABETES DEBATE - IS NEW BETTER?

DIABETES DEBATE - IS NEW BETTER? DIABETES DEBATE - IS NEW BETTER? WHAT MEDICATION CLASS AFTER METFORMIN TO CONTROL BLOOD SUGAR Dr. Lydia Hatcher, MD, CCFP, FCFP, CHE, D-CAPM Associate Clinical Professor of Family Medicine, McMaster Chief

More information

What s New in Type 2 Diabetes? 2018 Diabetes Updates

What s New in Type 2 Diabetes? 2018 Diabetes Updates What s New in Type 2 Diabetes? 2018 Diabetes Updates Jessica Conklin, PharmD, PhC, BCACP, CDE, AAHIP Associate Professor, UNM College of Phar macy jeconklin@salud.unm.edu Luis Gonzales, PharmD, PhC UNM

More information

Beyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM

Beyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM Beyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM Disclosures Jennifer D Souza has no conflicts of interest to disclose. 2 When Basal Insulin Is Not Enough Learning

More information

Objectives. Recognize all available medical treatment options for diabetes. Individualize treatment and glycemic target based on patient factors

Objectives. Recognize all available medical treatment options for diabetes. Individualize treatment and glycemic target based on patient factors No disclosure Objectives Recognize all available medical treatment options for diabetes Individualize treatment and glycemic target based on patient factors Should be able to switch to more affordable

More information

Wayne Gravois, MD August 6, 2017

Wayne Gravois, MD August 6, 2017 Wayne Gravois, MD August 6, 2017 Americans with Diabetes (Millions) 40 30 Source: National Diabetes Statistics Report, 2011, 2017 Millions 20 10 0 1980 2009 2015 2007 - $174 Billion 2015 - $245 Billion

More information

Agenda. Indications Different insulin preparations Insulin initiation Insulin intensification

Agenda. Indications Different insulin preparations Insulin initiation Insulin intensification Insulin Therapy F. Hosseinpanah Obesity Research Center Research Institute for Endocrine sciences Shahid Beheshti University of Medical Sciences November 11, 2017 Agenda Indications Different insulin preparations

More information

Multiple Factors Should Be Considered When Setting a Glycemic Goal

Multiple Factors Should Be Considered When Setting a Glycemic Goal Multiple Facts Should Be Considered When Setting a Glycemic Goal Patient attitude and expected treatment effts Risks potentially associated with hypoglycemia, other adverse events Disease duration Me stringent

More information

Ertugliflozin (Steglatro ) 5 mg daily. May increase to 15 mg daily. Take in the morning +/- food. < 60: Do not initiate; discontinue therapy

Ertugliflozin (Steglatro ) 5 mg daily. May increase to 15 mg daily. Take in the morning +/- food. < 60: Do not initiate; discontinue therapy Sodium-glucose Cotransporter-2 (SGLT2) s Inhibit SGLT in proximal renal tubules, reducing reabsorption of filtered glucose from tubular lumen Lowers renal threshold for glucose à increase urinary excretion

More information

DM Fundamentals Class 4 Meds for Type 2

DM Fundamentals Class 4 Meds for Type 2 DM Fundamentals Class 4 Meds for Type 2 Beverly Thomassian, RN, MPH, BC ADM, CDE President, Diabetes Education Services Copyright 1999 2015, Diabetes Education Services, All Rights Reserved. Diabetes Meds

More information

GLP-1 receptor agonists for type 2 diabetes currently available in the U.S.

GLP-1 receptor agonists for type 2 diabetes currently available in the U.S. GLP-1 receptor agonists for type 2 diabetes currently available in the U.S. GLP-1 agonists are a class of antidiabetic agents that mimic the actions of the glucagon-like peptide. GLP-1 is one of several

More information

The Death of Sulfonylureas? A Review of New Diabetes Medications

The Death of Sulfonylureas? A Review of New Diabetes Medications The Death of Sulfonylureas? A Review of New Diabetes Medications Kelly Hoenig, Pharm.D., BCPS Cedar Rapids Family Medicine Residency 2/4/17 Objectives Review GLP-1 Agonists, DPP-IV Inhibitors and SGLT-2

More information

FARXIGA (dapagliflozin) Jardiance (empagliflozin) tablets. Synjardy (empagliflozin and metformin hydrochloride) tablets. GLUCOPHAGE* (metformin)

FARXIGA (dapagliflozin) Jardiance (empagliflozin) tablets. Synjardy (empagliflozin and metformin hydrochloride) tablets. GLUCOPHAGE* (metformin) Type 2 Medications Drug Class How It Works Brand and Generic Names Manufacturers Usual Starting Dose The kidneys filter sugar and either absorb it back into your body for energy or remove it through your

More information

7/8/2016. Sol Jacobs MD, FACE Division of Endocrinology Emory University School of Medicine

7/8/2016. Sol Jacobs MD, FACE Division of Endocrinology Emory University School of Medicine Sol Jacobs MD, FACE Division of Endocrinology Emory University School of Medicine Participation in investigator initiated clinical research supported by: Merck Boehringer Ingelheim Novo Nordisk Astra Zeneca

More information

Joslin Diabetes Center Joslin Diabetes Forum 2013: The Impact of Comorbidities on Glucose Control Scenario 2: Reduced Renal Function

Joslin Diabetes Center Joslin Diabetes Forum 2013: The Impact of Comorbidities on Glucose Control Scenario 2: Reduced Renal Function Scenario 2: Reduced Renal Function 62 y.o. white man with type 2 diabetes for 18 years Hypertension and hypercholesterolemia Known proliferative retinopathy Current medications: Metformin 1000 mg bid Glyburide

More information

Achieving and maintaining good glycemic control is an

Achieving and maintaining good glycemic control is an Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE; Kathleen Wyne, MD, PhD, FACE, FNLA; Anthony Cannon,

More information

The Many Faces of T2DM in Long-term Care Facilities

The Many Faces of T2DM in Long-term Care Facilities The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment

More information

Individualizing Care for Patients with Type 2 Diabetes

Individualizing Care for Patients with Type 2 Diabetes Individualizing Care for Patients with Type 2 Diabetes Disclosures Speaker: AstraZeneca, Novo Nordisk, BI/Lilly, Valeritas, Takeda Advisor: Tandem Diabetes, Sanofi Objectives Develop individualized approaches

More information

Dept of Diabetes Main Desk

Dept of Diabetes Main Desk Dept of Diabetes Main Desk 01202 448060 Glucose management in Type 2 Diabetes in Adults The natural history of type 2 diabetes is for HbA1c to deteriorate with time. A stepwise approach to treatment is

More information

Hot Topics: The Future of Diabetes Management Cutting Edge Medication and Technology-Based Care

Hot Topics: The Future of Diabetes Management Cutting Edge Medication and Technology-Based Care Hot Topics: The Future of Diabetes Management Cutting Edge Medication and Technology-Based Care Mary Jean Christian, MA, MBA, RD, CDE Diabetes Program Coordinator UC Irvine Health Hot Topics: Diabetes

More information

Silvio E. Inzucchi MD Section of Endocrinology Yale School of Medicine

Silvio E. Inzucchi MD Section of Endocrinology Yale School of Medicine Gegia Chapter of the American Association of Clinical Endocrinologists, 2017 Annual Meeting January 28, 2017 Silvio E. Inzucchi MD Section of Endocrinology Yale School of Medicine DIABETES MANAGEMENT GUIDELINES

More information

DM Fundamentals Class 4 Meds for Type 2

DM Fundamentals Class 4 Meds for Type 2 DM Fundamentals Class 4 Meds for Type 2 Beverly Thomassian, RN, MPH, BC ADM, CDE President, Diabetes Education Services Copyright 1999 2015, Diabetes Education Services, All Rights Reserved. Diabetes Meds

More information

Glucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol

Glucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol Glucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed

More information

Professor Rudy Bilous James Cook University Hospital

Professor Rudy Bilous James Cook University Hospital Professor Rudy Bilous James Cook University Hospital Rate per 100 patient years Rate per 100 patient years 16 Risk of retinopathy progression 16 Risk of developing microalbuminuria 12 12 8 8 4 0 0 5 6

More information

Reviewing Diabetes Guidelines. Newsletter compiled by Danny Jaek, Pharm.D. Candidate

Reviewing Diabetes Guidelines. Newsletter compiled by Danny Jaek, Pharm.D. Candidate Reviewing Diabetes Guidelines Newsletter compiled by Danny Jaek, Pharm.D. Candidate AL AS KA N AT IV E DI AB ET ES TE A M Volume 6, Issue 1 Spring 2011 Dia bet es Dis pat ch There are nearly 24 million

More information

Insulin Initiation and Intensification. Disclosure. Objectives

Insulin Initiation and Intensification. Disclosure. Objectives Insulin Initiation and Intensification Neil Skolnik, M.D. Associate Director Family Medicine Residency Program Abington Memorial Hospital Professor of Family and Community Medicine Temple University School

More information

Disclosure. Learning Objectives. Case. Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare

Disclosure. Learning Objectives. Case. Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare Disclosure Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare Spring Therapeutics Update 2011 CSHP BC Branch Anar Dossa BScPharm Pharm D CDE April 20, 2011

More information

Help the Heart. An Update on GLP-1 Agonists and SGLT2 Inhibitors. Tara Hawley, PharmD PGY1 Pharmacy Resident Mayo Clinic Health System Eau Claire

Help the Heart. An Update on GLP-1 Agonists and SGLT2 Inhibitors. Tara Hawley, PharmD PGY1 Pharmacy Resident Mayo Clinic Health System Eau Claire Help the Heart An Update on GLP-1 Agonists and SGLT2 Inhibitors Tara Hawley, PharmD PGY1 Pharmacy Resident Mayo Clinic Health System Eau Claire Mayo Clinic Grand Rounds May 16, 2017 2017 MFMER slide-1

More information

DIABETES. overview of pharmacologic agents used in the management of. Overview 4/3/2014 OBJECTIVES. Injectable Agents

DIABETES. overview of pharmacologic agents used in the management of. Overview 4/3/2014 OBJECTIVES. Injectable Agents overview of pharmacologic agents used in the management of DIABETES Kyle Roberts, Pharm.D. PGY-1 Pharmacy Resident Saint Alphonsus RMC 1. List the different classes of diabetes medications, including the

More information

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal. Canagliflozin in combination therapy for treating type 2 diabetes

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal. Canagliflozin in combination therapy for treating type 2 diabetes NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal Canagliflozin in combination therapy for Final scope Remit/appraisal objective To appraise the clinical and cost effectiveness

More information

Steering Patients to Glycemic Control Using GLP-1 Receptor Agonists

Steering Patients to Glycemic Control Using GLP-1 Receptor Agonists Steering Patients to Glycemic Control Using GLP-1 Receptor Agonists IMPROVING T2DM OUTCOMES IN THE PHARMACY SETTING Release Date: July 31, 2015 Expiration Date: July 31, 2016 Presented by Creative Educational

More information

Diabetes Mellitus II CPG

Diabetes Mellitus II CPG 1 Diabetes Mellitus II CPG Candidates for Screening Integrated Complex Care Patients: Check Yearly Prediabetes: Check Yearly No Diabetes Mellitus (DM) Risk Factors: Check at Age 45, Repeat Every 3 Years

More information

TREATMENT OF DIABETES AFTER METFORMIN GREGG GERETY, MD ALBANY MEDICAL COLLEGE, DIVISION OF COMMUNITY ENDOCRINOLOGY JULY 14, 2017

TREATMENT OF DIABETES AFTER METFORMIN GREGG GERETY, MD ALBANY MEDICAL COLLEGE, DIVISION OF COMMUNITY ENDOCRINOLOGY JULY 14, 2017 TREATMENT OF DIABETES AFTER METFORMIN GREGG GERETY, MD ALBANY MEDICAL COLLEGE, DIVISION OF COMMUNITY ENDOCRINOLOGY JULY 14, 2017 Outline Review treatment algorithms from ADA/ EASD & ACE/AACE. Review positive

More information

Initiating Injectable Therapy in Type 2 Diabetes

Initiating Injectable Therapy in Type 2 Diabetes Initiating Injectable Therapy in Type 2 Diabetes David Doriguzzi, PA C Learning Objectives To understand current Diabetes treatment guidelines To understand how injectable medications fit into current

More information

Making Sense of Mediations for Diabetes

Making Sense of Mediations for Diabetes Making Sense of Mediations for Diabetes Lisa Kroon, PharmD, CDE Professor of Clinical Pharmacy UCSF School of Pharmacy Diabetes Mellitus: U.S. Impact Source: ADA; released June 10, 2014 ~1-1.5 Million

More information

Images have been removed from the PowerPoint slides in this handout due to copyright restrictions. Insulins. Rapid Short Intermediate Long Mix

Images have been removed from the PowerPoint slides in this handout due to copyright restrictions. Insulins. Rapid Short Intermediate Long Mix Diabetes Medications Diabetes Medications Type 1 Insulin is needed Type 2 Oral Diabetes Medications Or Oral Diabetes Medications plus Insulin Or Insulin Alone Diabetes Medications Secretagogues Glipizide

More information

A Practical Approach to the Use of Diabetes Medications

A Practical Approach to the Use of Diabetes Medications A Practical Approach to the Use of Diabetes Medications Juan Pablo Frias, M.D., FACE President, National Research Institute, Los Angles, CA Clinical Faculty, University of California, San Diego, CA OUTLINE

More information

Diabetes Mellitus. Intended Learning Objectives:

Diabetes Mellitus. Intended Learning Objectives: Intended Learning Objectives: Diabetes Mellitus 1. Compare and contrast the differences between the drug therapy recommendations of several of the latest and leading diabetes guidelines. 2. Assess the

More information

Drug Class Review Newer Diabetes Medications and Combinations

Drug Class Review Newer Diabetes Medications and Combinations Drug Class Review Newer Diabetes Medications and Combinations Final Update 2 Report July 2016 The purpose reports is to make available information regarding the comparative clinical effectiveness and harms

More information

Type 2 Diabetes Management: Case 1: Reducing Hypoglycemic Risk Case 2: Reducing Cardiovascular Risk

Type 2 Diabetes Management: Case 1: Reducing Hypoglycemic Risk Case 2: Reducing Cardiovascular Risk Type 2 Diabetes Management M. Susan Burke, MD, FACP Clinical Associate Professor of Medicine Sidney Kimmel Medical College at Thomas Jefferson University Senior Advisor, Lankenau Medical Associates Lankenau

More information

2018 Diabetes Summit Managing Diabetes: An Art and a Science

2018 Diabetes Summit Managing Diabetes: An Art and a Science 2018 Diabetes Summit Managing Diabetes: An Art and a Science Natasha Petry, PharmD, BCACP NDSU College of Health Professions, School of Pharmacy, Department of Pharmacy Practice Patient-Centered Medical

More information

STEP THERAPY CRITERIA

STEP THERAPY CRITERIA CATEGORY DRUG CLASS BRAND NAME (generic) STEP THERAPY CRITERIA AMYLIN ANALOG: SYMLIN/SYMLINPEN (pramlintide acetate) ANTIDIABETIC AGENTS GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1): ADLYXIN (lixisenatide)

More information

MOA: Long acting glucagon-like peptide 1 receptor agonist

MOA: Long acting glucagon-like peptide 1 receptor agonist Alexandria Rydz MOA: Long acting glucagon-like peptide 1 receptor agonist Increases glucose dependent insulin secretion Decreases inappropriate glucagon secretion Increases β- cell growth and replication

More information

This program applies to Commercial, GenPlus and Health Insurance Marketplace formularies.

This program applies to Commercial, GenPlus and Health Insurance Marketplace formularies. OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) Agonists [Adlyxin (lixisenatide), Byetta (exenatide), Bydureon (exenatide extended-release), Tanzeum (albiglutide), Trulicity (dulaglutide),

More information

RPCC Pharmacy Forum. The Type 2 Diabetes Issue. Type 2 Diabetes: The Basics

RPCC Pharmacy Forum. The Type 2 Diabetes Issue. Type 2 Diabetes: The Basics Nov/Dec 2015 Issue 11 RPCC Pharmacy Forum Special Interest Articles: Diabetes Medication Chart Insulin Chart Afreeza Did you know? Exanatide, marketed as Byetta, is the synthetic form of exendin-4, which

More information

Pharmacology Updates. Quang T Nguyen, FACP, FACE, FTOS 11/18/17

Pharmacology Updates. Quang T Nguyen, FACP, FACE, FTOS 11/18/17 Pharmacology Updates Quang T Nguyen, FACP, FACE, FTOS 11/18/17 14 Classes of Drugs Available for the Treatment of Type 2 DM in the USA ### Class A1c Reduction Hypoglycemia Weight Change Dosing (times/day)

More information

3/8/2011. Julie M. Sease, Pharm D, BCPS, CDE Associate Professor of Pharmacy Practice Presbyterian College School of Pharmacy

3/8/2011. Julie M. Sease, Pharm D, BCPS, CDE Associate Professor of Pharmacy Practice Presbyterian College School of Pharmacy Summarize revisions to the 2011 American Diabetes Association clinical practice guidelines. Evaluate bromocriptine as a therapeutic option in the management of type 2 diabetes. Compare and contrast the

More information

Keep Calm and Focus on the Evidence for the Management of Diabetes. Diabetes Update 2018

Keep Calm and Focus on the Evidence for the Management of Diabetes. Diabetes Update 2018 Keep Calm and Focus on the Evidence for the Management of Diabetes Diabetes Update 2018 Nicole C.Pezzino, PharmD, BCACP, CDE Assistant Professor, Wilkes University Pharmacist, Weis Markets Nicole.pezzino@wilkes.edu

More information

Type. Diabetes Drugs. A Review

Type. Diabetes Drugs. A Review Type Diabetes is a common diagnosis for home care patients. Diabetes drugs are now available that target the multiple defects of metabolism that characterize Type 2 diabetes. Understanding the wide variety

More information

CASE A2 Managing Between-meal Hypoglycemia

CASE A2 Managing Between-meal Hypoglycemia Managing Between-meal Hypoglycemia 1 I would like to discuss this case of a patient who, overall, was doing well on her therapy until she made an important lifestyle change to lose weight. This is a common

More information

Objectives. How Medicine Works to Control Blood Sugar Levels. What Happens When We Eat? What is diabetes? High Blood Glucose (Hyperglycemia)

Objectives. How Medicine Works to Control Blood Sugar Levels. What Happens When We Eat? What is diabetes? High Blood Glucose (Hyperglycemia) How Medicine Works to Control Blood Sugar Levels Stacie Petersen, RN, CDE Objectives Define Diabetes List how medications work (ominous octet) Identify side effects of medications for diabetes What is

More information

Overview T2DM medications. Winnie Ho

Overview T2DM medications. Winnie Ho Overview T2DM medications Winnie Ho Diabetes in Australia 1.7 million Australians with diabetes, of these 85% have T2DM 2-fold excess risk CV death in patients with diabetes Risk factor for progression

More information

Side Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors. Bryce Fukunaga PharmD April 25, 2018

Side Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors. Bryce Fukunaga PharmD April 25, 2018 Side Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors Bryce Fukunaga PharmD April 25, 2018 Objectives For each drug class: Identify the overall place in therapy Explain the mechanism of action

More information

Let s not sugarcoat it! Update on Pharmacologic Management of Type II DM

Let s not sugarcoat it! Update on Pharmacologic Management of Type II DM Let s not sugarcoat it! Update on Pharmacologic Management of Type II DM Gregory Castelli, PharmD, BCPS, BC-ADM Clinical Pharmacist UPMC St. Margaret Objectives By the end of this presentation, participants

More information

Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Prior Authorization Protocol

Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Prior Authorization Protocol Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed

More information

Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol

Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has

More information

How can we improve outcomes in Type 2 diabetes?

How can we improve outcomes in Type 2 diabetes? How can we improve outcomes in Type 2 diabetes? Earlier diagnosis Better patient education Stress central role of lifestyle management Identify and treat all risk factors Use rational pharmacological therapy

More information

DIABETES UPDATE 2018

DIABETES UPDATE 2018 DIABETES UPDATE 2018 Jerome V. Tolbert, M.D., Ph.D. Assistant Professor of Medicine Icahn School of Medicine at Mt. Sinai Division of Endocrinology and Bone Diseases 317 East 17 th Street New York, New

More information

Jonathan Stoehr, MD PhD Endocrinology, Diabetes, Metabolism and Nutrition Virginia Mason Medical Center Seattle, WA 2012 Virginia Mason Medical

Jonathan Stoehr, MD PhD Endocrinology, Diabetes, Metabolism and Nutrition Virginia Mason Medical Center Seattle, WA 2012 Virginia Mason Medical Jonathan Stoehr, MD PhD Endocrinology, Diabetes, Metabolism and Nutrition Virginia Mason Medical Center Seattle, WA There is no conflict of interest that could be perceived as prejudicing the impartiality

More information

GLP-1-based therapies in the management of type 2 diabetes

GLP-1-based therapies in the management of type 2 diabetes GLP-1-based therapies in the management of type 2 diabetes Makbul Aman Mansyur Division Endocrine & Metabolism Department of Internal Medicine Faculty of Medicine Hasanuddin University/ RSUP Dr. Wahidin

More information

Diabetes Medication Updates Erica Bukovich, PharmD, BC-ADM, CDE September 20, 2018

Diabetes Medication Updates Erica Bukovich, PharmD, BC-ADM, CDE September 20, 2018 Diabetes Medication Updates Erica Bukovich, PharmD, BC-ADM, CDE September 20, 2018 Learning Objectives Identify medication classes available for treatment of individuals with diabetes. Demonstrate understanding

More information

DM-2 Therapy Update: GLP-1, SGLT-2 Inhibitors, and Inhaled Insulin, Oh My!

DM-2 Therapy Update: GLP-1, SGLT-2 Inhibitors, and Inhaled Insulin, Oh My! DM-2 Therapy Update: GLP-1, SGLT-2 Inhibitors, and Inhaled Insulin, Oh My! Kevin M. Pantalone, DO, ECNU, CCD Associate Staff Director of Clinical Research Department of Endocrinology Endocrinology and

More information

2/9/2016. The Evolving Armamentarium for Type 2 Diabetes: Incorporating New Classes in the Treatment of Our Patients. Objectives: Pharmacists

2/9/2016. The Evolving Armamentarium for Type 2 Diabetes: Incorporating New Classes in the Treatment of Our Patients. Objectives: Pharmacists WAYNE STATE UNIVERSITY COLLEGE OF PHARMACY & HEALTH SCIENCES FEBRUARY 28, 2016 The Evolving Armamentarium for Type 2 Diabetes: Clinical Assistant Professor, Department of Pharmacy Practice Ambulatory Care

More information

Date of Review: September 2016 Date of Last Review: September 2015

Date of Review: September 2016 Date of Last Review: September 2015 Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy

Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline

More information

Faculty. Concentrated Insulin: Examining the Necessity of Newer Insulins for In-Hospital Diabetes Management. Disclosures. Learning Objectives

Faculty. Concentrated Insulin: Examining the Necessity of Newer Insulins for In-Hospital Diabetes Management. Disclosures. Learning Objectives Examining the Necessity of Newer Insulins for In-Hospital Diabetes Management Faculty Susan Cornell, PharmD, CDE, FAPhA, FAADE Associate Professor of Pharmacy Practice Associate Director of Experiential

More information

YOU HAVE DIABETES. Angie O Connor Community Diabetes Nurse Specialist 25th September 2013

YOU HAVE DIABETES. Angie O Connor Community Diabetes Nurse Specialist 25th September 2013 YOU HAVE DIABETES Angie O Connor Community Diabetes Nurse Specialist 25th September 2013 Predicated 2015 figures are already met 1 in 20 have diabetes:1in8 over 60years old Definite Diagnosis is key Early

More information

8/12/2016. Diabetes Management Across the Spectrum of Kidney Function. Andrew Bzowyckyj. Learning Objectives. Ashley Crowl

8/12/2016. Diabetes Management Across the Spectrum of Kidney Function. Andrew Bzowyckyj. Learning Objectives. Ashley Crowl Diabetes Management Across the Spectrum of Kidney Function Andrew Bzowyckyj PharmD, BCPS, CDE Clinical Assistant Professor School of Pharmacy University of Missouri-Kansas City Kansas City, MO Ashley Crowl

More information

Very Practical Tips for Managing Type 2 Diabetes

Very Practical Tips for Managing Type 2 Diabetes Very Practical Tips for Managing Type 2 Diabetes Jean-François Yale, MD, FRCPC McGill University Health Centre, Montreal, Canada Jean-francois.yale@mcgill.ca www.dryale.ca OBJECTIVES DISCLOSURES The participant

More information

Multiple Small Feedings of the Mind: Diabetes. Sonja K Fredrickson, MD, BC-ADM March 7, 2014

Multiple Small Feedings of the Mind: Diabetes. Sonja K Fredrickson, MD, BC-ADM March 7, 2014 Multiple Small Feedings of the Mind: Diabetes Sonja K Fredrickson, MD, BC-ADM March 7, 2014 Question 1: Setting A1c Goals Describe the evidence based approach to determining the target HgbA1c in different

More information

Non-Insulin Diabetes Medications Summary

Non-Insulin Diabetes Medications Summary Non-Insulin Diabetes Medications Summary Medications marked with an asterisk (*) can cause hypoglycemia INSULIN SECRETAGOGUES Sulfonylureas* GLYBURIDE* (Diabeta) (Micronase) production. Side effects: Potential

More information

The Diabetes Guidelines Trek: The Next Generation. Inpatient Diabetes Guidelines. Learning Objectives. Current Inpatient Guidelines

The Diabetes Guidelines Trek: The Next Generation. Inpatient Diabetes Guidelines. Learning Objectives. Current Inpatient Guidelines The Diabetes Guidelines Trek: The Next Generation J. Christopher Lynch, PharmD, BCACP Southern Illinois University Edwardsville School of Pharmacy Susan Cornell BS, PharmD, CDE, FAPhA, FAADE Midwestern

More information

Diabetes Mellitus: Overview and Guidelines

Diabetes Mellitus: Overview and Guidelines Diabetes Mellitus: Overview and Guidelines Rezvan Salehidoost, M.D., Endocrinologist Abidi Diabetes Master Class IMPORTANCE? Why is it interesting to do research in diabetes J. Olefsky, JAMA 2001:285:628-632

More information

Glucose Control drug treatments

Glucose Control drug treatments Glucose Control drug treatments It should be noted that glitazones are under suspicion of precipitating acute cardiac events and current recommendations contraindicate the use of glitazones in patients

More information

Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE. CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010

Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE. CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010 Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE Robert R. Henry, MD Authors and Disclosures CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010 Introduction Type 2 diabetes

More information

4/9/2018 HOW TO REGULATE DIABETES MEDICATIONS. By Sarah Froemsdorf MSN, RNC, CDE, FNP DISCLOSURES NONE. Diagnosis

4/9/2018 HOW TO REGULATE DIABETES MEDICATIONS. By Sarah Froemsdorf MSN, RNC, CDE, FNP DISCLOSURES NONE. Diagnosis HOW TO REGULATE DIABETES MEDICATIONS By Sarah Froemsdorf MSN, RNC, CDE, FNP DISCLOSURES NONE Diagnosis 1 NORMAL BODY The normal pancreas releases one unit of insulin every hour all day. The normal pancreas

More information

SGLT2 Inhibitors

SGLT2 Inhibitors Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: SGLT2 Inhibitors Page: 1 of 7 Last Review Date: June 22, 2018 SGLT2 Inhibitors Description Invokana

More information

Drugs used in Diabetes. Dr Andrew Smith

Drugs used in Diabetes. Dr Andrew Smith Drugs used in Diabetes Dr Andrew Smith Plan Introduction Insulin Sensitising Drugs: Metformin Glitazones Insulin Secretagogues: Sulphonylureas Meglitinides Others: Acarbose Incretins Amylin Analogues Damaglifozin

More information

Newer and Expensive treatment of diabetes. Endocrinology Visiting Associate Professor Institute of Medicine TUTH

Newer and Expensive treatment of diabetes. Endocrinology Visiting Associate Professor Institute of Medicine TUTH Newer and Expensive treatment of diabetes Jyoti Bhattarai MD Endocrinology Visiting Associate Professor Institute of Medicine TUTH Four out of every five people with diabetes now live in developing countries.

More information

Early treatment for patients with Type 2 Diabetes

Early treatment for patients with Type 2 Diabetes Israel Society of Internal Medicine Kibutz Hagoshrim, June 22, 2012 Early treatment for patients with Type 2 Diabetes Eduard Montanya Hospital Universitari Bellvitge-IDIBELL CIBERDEM University of Barcelona

More information

Newer Diabetes Treatments Drug Class Update with New Drug Evaluation: Semaglutide and Ertugliflozin

Newer Diabetes Treatments Drug Class Update with New Drug Evaluation: Semaglutide and Ertugliflozin Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

9/12/2014. Main Pathophysiological Defect in T1DM. Main Pathophysiological Defects in T2DM. Personalizing Diabetes Care: The Alphabet Soup of Options

9/12/2014. Main Pathophysiological Defect in T1DM. Main Pathophysiological Defects in T2DM. Personalizing Diabetes Care: The Alphabet Soup of Options 9/12/2014 Baptist Health South Florida 13th Annual Primary Focus Symposium June 28, 2014 Silvio Inzucchi MD Section of Endocrinology Yale University School of Medicine Half-Century of HTN & T2DM Medications

More information

Medical therapy advances London/Manchester RCP February/June 2016

Medical therapy advances London/Manchester RCP February/June 2016 Medical therapy advances London/Manchester RCP February/June 2016 Advances in medical therapies for diabetes mellitus Duality of interest: The speaker or institutions with which he is associated has received

More information

Exploring Non-Insulin Therapies in Type 1 Diabetes

Exploring Non-Insulin Therapies in Type 1 Diabetes Exploring Non-Insulin Therapies in Type 1 Diabetes Susan Cornell, BS, PharmD, CDE, FAPhA, FAADE Associate Professor Midwestern University - Chicago College of Pharmacy Disclosures Dr. Cornell: Advanced

More information